<DOC>
	<DOCNO>NCT01533714</DOCNO>
	<brief_summary>The primary objective study ass long-term safety CDP6038 .</brief_summary>
	<brief_title>The Long-term Safety Efficacy Olokizumab ( CDP6038 ) With Active Rheumatoid Arthritis</brief_title>
	<detailed_description>Eligible subject enter study complete Week 12 Visit RA0083 [ NCT01463059 ] allow continue open-label study approval marketing application indication Rheumatoid Arthritis ( RA ) subject 's country region , notice UCB . All subject receive subcutaneous ( sc ) injection CDP6038 120 mg every 2 week ( q2w ) throughout study , regardless treatment assignment RA0083 [ NCT01463059 ] .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Completed RA0083 [ NCT01463059 ] study ( Week 12 Visit ) Must maintain stable dose ( route ) methotrexate ( MTX ) 6 16 mg/week Japan 7.5 20 mg/week Korea Taiwan RA0083 [ NCT01463059 ] , plan maintain dose route administration least 12 week Female subject must either postmenopausal least 1 year , surgically incapable childbearing , effectively practice 2 acceptable method contraception Have ongoing SAE RA0083 [ NCT01463059 ] study Female subject breastfeed , pregnant , plan become pregnant study within 24 week Have evidence active latent tuberculosis ( TB ) Subject receive biologic response modifier synthetic diseasemodifying antirheumatic drug ( DMARD ) MTX Subject plan surgery first 12 week study Subjects test positive hepatitis B core antibody ( HBcAb ) and/or hepatitis B surface antibody ( HBsAb ) Screening RA0083 [ NCT01463059 ] subsequently test positive hepatitis B virus deoxyribonucleic acid ( HBV DNA ) Week 12 RA0083 [ NCT01463059 ]</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Interleukin-6</keyword>
	<keyword>Olokizumab</keyword>
	<keyword>CDP6038</keyword>
</DOC>